Columbia Labs won't give up on controlled-release vaginal gel

Columbia Laboratories ($CBRX) is slashing 42% of its workforce in light of the FDA's recent rejection of a vaginal progesterone gel it is developing with Watson Pharmaceuticals ($WPI). The product incorporates Columbia's bioadhesive drug delivery technology, which uses the bioadhesive polymer polycarbophil to bond to mucosal surfaces in the body, after which it discharges the drug it carries using controlled release. Columbia is making the majority of its 10 cuts in research and development and administration; 24 positions will remain. Moving forward, the company said it is considering "all strategic options" and will continue to try advancing its vaginal progesterone gel to regulatory approval. Story

Suggested Articles

J&J figures its partner Genmab owes a share of Darzalex Faspro royalties to Halozyme for its subcutaneous delivery tech. Genmab doesn't agree.

Bexson Biomedical and Stevanato Group teamed up to develop a ketamine pump that may help patients better manage pain at home.

Australia's University of New South Wales and Uka Tarsadia University in India will join forces to explore contact lenses for ocular drug delivery.